Roll No:

MPHARM
(SEM I) THEORY EXAMINATION 2021-22
PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS-I

Time: 3 Hours *Total Marks: 75*

Note: 1. Attempt all Sections. If require any missing data; then choose suitably.

SECTION A

1. Attempt *all* questions in brief. **10 x 2 = 20**

a.	Differentiate between Wistar rat and Sprague Dawley rat.
b.	Enlist various types of bioassays.
c.	List the models for screening antiepileptics.
d.	Distinguish between homogenous and heterogeneous immunoassay.
e.	State the animal models for screening anti-ulcer drugs.
f.	Recall some methods of performing euthanasia.
g.	Define 'Nootropics' and name the models for its evaluation.
h.	State the preclinical screening models for evaluating anti-emetics.
i.	Compare interoceptive and exteroceptive anti-anxiety models.
j.	Categorize models for screening analgesics.

SECTION B

2. Attempt any *two* parts of the following: **2 x 10 = 20**

a.	Explain the *in-vitro* and *in-vivo* methods used for screening anti-cancer drugs.
b.	Discuss the pre-clinical screening methods for evaluating anti-inflammatory and anti-pyretic drugs.
c.	Illustrate the preclinical screening models for evaluation of antidiabetics.

SECTION C

3. Attempt any *five* parts of the following: **7 x 5 = 35**

a.	Discuss the animal models for screening anti-psychotics.
b.	Explain the production and application of transgenic animals.
c.	Describe the methods used for screening anti-Parkinson drugs.
d.	Demonstrate the immunoassay of insulin or digoxin.
e.	Illustrate the pre-clinical screening models for anti-hypertensive drugs.
f.	Define immunomodulators. Discuss the *in-vivo* and *in-vitro* models for screening them.
g.	Describe the CPCSEA guidelines to conduct experiments on animals.

https://www.aktuonline.com